Will Becton, Dickinson (BDX) Stock Jump Following its Q2 Report?

What's Happening With BDX View more about BDX >

Becton, Dickinson & Co. (BDX) reports fiscal second-quarter numbers before the market open May 9. Analysts expect earnings of $2.59 per share on sales of $4.24 billion, versus $2.65 on revenue of $4.22 billion the same period last year. BDX is up a modest 4.7% on the year.

Technical Analysis

BDX stock was recently trading at $236.01 down $29.86 from its 12-month high and $27.39 above its 12-month low. InvestorsObserver’s Stock Score Report gives BDX a 49 long-term technical score and a 61 short-term technical score. The stock has recent support above $225 and recent resistance below $250. Of the 16 analysts who cover the stock 11 rate it Strong Buy, 0 rate it Buy, 5 rate it Hold, 0 rate it Sell, and 0 rate it Strong Sell, BDX gets a score of 61 from InvestorsObserver’s Stock Score Report.

Analysts' Thoughts

BDX stock has been a volatile stock over the last year, with some big moves in both directions. The company has shown good earnings growth in recent years with profits up just shy of 15% per annum over the last five years and analysts forecast earnings to rise at an annual rate of 11.7% over the next five years. BDX stock trades at just 17 times future earnings which should allow the stock to move higher as long as the company is able to hit its future estimates. Last quarter the company topped estimates on both the top and bottom line, and it has posted positive earnings surprises 17 out of the last 18 quarters. Analysts see upside in the stock with an average price target of $267.75 versus its current price of $236.40.

BDX
About Becton Dickinson and Company

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. International revenue accounts for 45% of the company's business. With CareFusion, BD has entered into medical systems (such as infusion pumps and ventilators) as well as procedural solutions businesses. The Bard deal gives the company a presence in urology, vascular, and oncology.

  • Last Price:
    $235.19
  • Previous Close:
    $234.00
  • Change:
    $1.19 (0.51%)
  • Open:
    $234.89
  • Volume:
    1,290,884
  • Average Volume (100 Day):
    1,268,658
  • Market Capitalization:
    $63.4 B
  • Day's Range:
    $234.12 - $238.33
  • Dividend Yield:
    1.32%
  • 52-week Range:
    $266 - $208.62
  • P-E:
    70.10
  • EPS:
    $3.34
  • Earnings Date:
    8/1/19
  • Ex Dividend Date:
    6/6/19
  • Sector:
    Healthcare
  • Industry:
    Medical Instruments & Supplies
  • Analyst Average Recommendation:
    Moderate Buy

Already a member?

Login to see your Stocks to Watch Trade Ideas.

Not yet a member?

Receive a Morning Action trade idea every market day in the Morning Update, plus Stocks to Watch Trade Ideas every Saturday.

Become A Member

|